Lixisenatide (revision 7)

Lixisenatide is a GLP-1 receptor agonist derived from exendin-4, the same scaffold as exenatide, with a modified C-terminus. It is short-acting and given once daily.^[1]

Its pharmacological profile emphasises postprandial glycaemic control through pronounced delay of gastric emptying, an effect that does not attenuate as it does with continuously present long-acting agonists.^[2]

The ELIXA trial randomised people with type 2 diabetes and a recent acute coronary syndrome and reported no difference in cardiovascular outcomes. That neutral result is one of the principal reasons cardiovascular benefit is not treated as a class property.^[1]

Like exenatide, lixisenatide carries glycine at position 2 of the exendin scaffold and is therefore not a substrate for DPP-4. Its half-life of about three hours nonetheless requires daily dosing, since renal clearance dominates once proteolysis is removed.^[2]

The short exposure profile produces a large gastric-emptying effect at each dose, and it is this rather than a large fasting-glucose effect that drives its glycaemic action. Its effect on glycated haemoglobin is modest by current standards.^[1]

Non-attenuating emptying delay is a genuine pharmacological difference from the weekly agents and is the reason short-acting agents retain a niche where postprandial excursions are the problem.^[2]